Sanofi takes a place in the top five companies of the 2021 Access to Medicine index, recognizing its work to making medicines more easily available in low- and middle-income countries. 

Published every two years, the Access to Medicine index reports how 20 pharmaceutical companies make medicines, vaccines and diagnostics more accessible for people living in low- and middle-income countries.

Sanofi ranks fifth for 2021, moving up two places in the overall ranking compared to the last rankings, performing particularly strongly in two categories:

  • Research & Development (4th place): Sanofi is developing access plans for six of its late-stage priority R&D projects targeting priority diseases of the Index to ensure populations living in low- and middle-income countries have access to its new products, shortly after the first launch. For instance, Sanofi is planning to proceed with a WHO prequalification of its pediatric hexavalent vaccine and a registration in low-and middle-income countries to make the vaccine accessible to GAVI countries. 
    Sanofi is also involved in high quality capacity building initiatives, such as the Seeding Labs Instrumental Access program, which supports scientific progress and builds R&D capacities in low- and middle-income countries by providing scientists with surplus lab equipment, training and the opportunity to collaborate with experts in their field. 
  • Product Delivery (3rd place): Sanofi has affordable access strategies in place for most of its existing products: Sanofi extended the conditions of the Unitaid agreement on a price reduction of a latent tuberculosis drug to South Africa, one of the countries with a high-burden of the disease; Sanofi is leading the health system strengthening initiatives with the Kids and Diabetes at School (KiDS) program to develop better understanding of type 1 and type 2 diabetes among children, teachers, school nurses and parents or with the Fight Against Stigma (FAST) initiative to train health workers, raise public awareness  and educate patients and their family to improve access to care for patients living with mental disorders or epilepsy; Sanofi works to control, eliminate and eradicate some neglected tropical diseases, most notably through drugs donations to eliminate sleeping sickness. 

“We are proud to be part of the top five of the 2021 ATM index,” says Sandrine Bouttier-Stref, Global Head of Corporate Social Responsibility, Sanofi. “This recognition demonstrates our strong commitment to increase access to healthcare to the most vulnerable populations of the world, which is a key pillar of our new contract with society.” 

Indeed, Sanofi’s new Corporate Social Responsibility strategy focuses on sustainable solutions to address access challenges, especially with the delivery of essential medicines to the poorest countries in the world through a dedicated unit, together with a humanitarian commitment on rare diseases and on access planning for its pipeline.